Jean Jacques Bienaime - 29 Apr 2022 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Chief Executive Officer, Director
Signature
/s/ Laura Randall Woodhead, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
29 Apr 2022
Net transactions value
-$1,316,319
Form type
4
Filing time
09 May 2022, 21:29:46 UTC
Previous filing
02 May 2022
Next filing
17 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Award $21,281 +341 +0.1% $62.41 335,324 29 Apr 2022 Direct F1
transaction BMRN Common Stock Options Exercise $374,600 +10,000 +3% $37.46 345,324 05 May 2022 Direct F2
transaction BMRN Common Stock Sale $841,400 -10,000 -2.9% $84.14 335,324 05 May 2022 Direct F2
transaction BMRN Common Stock Options Exercise $749,200 +20,000 +6% $37.46 355,324 06 May 2022 Direct F3
transaction BMRN Common Stock Sale $1,620,000 -20,000 -5.6% $81.00 335,324 06 May 2022 Direct F3
holding BMRN Common Stock 247,533 29 Apr 2022 Shares held by Jean-Jacques Bienaime Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -10,000 -33% $0.000000 20,000 05 May 2022 Common Stock 10,000 $37.46 Direct F2, F4
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -20,000 -100% $0.000000* 0 06 May 2022 Common Stock 20,000 $37.46 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired by the reporting person on April 29, 2022, pursuant to the issuer's Employee Stock Purchase Plan.
F2 Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022.
F3 Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022. Mr. Bienaime's former spouse will receive approximately 73% of the net proceeds from the shares sold in this transaction pursuant to a marital separation agreement between her and Mr. Bienaime.
F4 Reflects the number of options outstanding after the transactions from this specific stock option grant.